MRC RT01: an important trial

被引：3

作者：

Denham, James W. ^{[1
]}

机构：

[1] Univ Newcastle, Mater Hosp, Callaghan, NSW, Australia

来源：

LANCET ONCOLOGY | 2007年 / 8卷 / 06期

关键词：

LOCALIZED PROSTATE-CANCER; ANDROGEN DEPRIVATION; DOSE-RESPONSE; RADIOTHERAPY; THERAPY;

D O I：

10.1016/S1470-2045(07)70152-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：459 / 460

页数：2

共 10 条

[1] Delayed rectal and urinary symptomatotogy in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation
Christie, D
Denham, J
Steigler, A
Lamb, D
Turner, S
Mameghan, H
Joseph, D
Matthews, J
Franklin, I
Atkinson, C
North, J
Poulsen, M
Spry, NA
Tai, KH
Wynne, C
Duchesne, G
Kovacev, O
Francis, L
Kramar, A
D'Este, C
Bill, D
[J]. RADIOTHERAPY AND ONCOLOGY, 2005, 77 (02) : 117 - 125
[2] Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
Collette, Laurence
Burzykowski, Tomasz
Schroder, Fritz H.
[J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (10) : 1344 - 1350
[3] Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
Dearnaley, David P.
Sydes, Matthew R.
Graham, John D.
Aird, Edwin G.
Bottomley, David
Cowan, Richard A.
Huddart, Robert A.
Jose, Chakiath C.
Matthews, John H. L.
Millar, Jeremy
Moore, A. Rollo
Morgan, Rachel C.
Russell, J. Martin
Scrase, Christopher D.
Stephens, Richard J.
Syndikus, Isabel
Parmar, Mahesh K. B.
[J]. LANCET ONCOLOGY, 2007, 8 (06) : 475 - 487
[4] Non-parametric methods for analysing recurrent complications of varying severity
Lancar, R
Kramar, A
HaieMeder, C
[J]. STATISTICS IN MEDICINE, 1995, 14 (24) : 2701 - 2712
[5] Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy
Peeters, STH
Heemsbergen, WD
Koper, PCM
van Putten, WLJ
Slot, A
Dielwart, MFH
Bonfrer, JMG
Incrocci, L
Lebesque, AV
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) : 1990 - 1996
[6] Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial
Pollack, A
Zagars, GK
Starkschall, G
Antolak, JA
Lee, JJ
Huang, E
von Eschenbach, AC
Kuban, DA
Rosen, I
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (05): : 1097 - 1105
[7] Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Roach, Mack, III
Hanks, Gerald
Thames, Howard, Jr.
Schellhammer, Paul
Shipley, William U.
Sokol, Gerald H.
Sandler, Howard
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (04): : 965 - 974
[8] Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European organisation for research and treatment of cancer (EORTC) trial 30891
Studer, UE
Whelan, P
Albrecht, W
Casselman, J
de Reijke, T
Hauri, D
Loidl, W
Isorna, S
Sundaram, SK
Debois, M
Collete, L
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) : 1868 - 1876
[9] Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer
Vicini, FA
Vargas, C
Abner, A
Kestin, L
Horwitz, E
Martinez, A
[J]. JOURNAL OF UROLOGY, 2005, 173 (05) : 1456 - 1462
[10] Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate - A randomized controlled trial
Zietman, AL
DeSilvio, ML
Slater, JD
Rossi, CJ
Miller, DW
Adams, JA
Shipley, WU
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (10): : 1233 - 1239

← 1 →